Gastrocnemius Myofascial Release in Females With Knee Osteoarthritis
Key facts
- Where
- Giza, EgyptSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 55 years old?
Source: NCT07507175, who can take part
Where in Egypt
- Faculty of Physical Therapy, Cairo UniversityGiza, EgyptContact: Afaf Omar TahoonTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Cairo University
- Trial code
- NCT07507175
- Record updated
- 2 April 2026
- Original description
The goal of this clinical trial is to determine whether gastrocnemius myofascial release is effective in reducing pain and improving physical function in females with knee osteoarthritis.Read full original descriptionShow less
Effect of Gastrocnemius Myofascial Release on Pain and Physical Function Outcomes in Females With Knee Osteoarthritis
The goal of this clinical trial is to determine whether gastrocnemius myofascial release is effective in reducing pain and improving physical function in females with knee osteoarthritis.
The main question this study aims to answer are:
* Does adding gastrocnemius MFR to conventional physical therapy treatment influence pain, physical function, foot posture, and knee disability compared to conventional physical therapy treatment and sham MFR in knee osteoarthritis? * Participants receive gastrocnemius myofascial release treatment or sham gastrocnemius myofascial release treatment for 3 times weekly for 4 weeks for both groups.
Inclusion: Patients' ages ranged between 45 and 55 years ; BMI ≤35; Patients with a diagnosis of primary KOA according to the American College of Rheumatology classification at the screening visit ; Onset of symptomatic knee osteoarthritis of ≥3 months; Patients with grade II and III OA of the Kellgren and Lawrence system for classification of osteoarthritis ; At least one active trigger point in GM; If both knees were diagnosed as OA, the most affected one was selected; Current pain intensity on the Visual Analogue Scale (VAS) ≥4/10; Subjects have sufficient cognition that enables them to understand the requirements of the study, comply with the study procedures, and visit schedule; Diagnostic Criteria of KOA; A diagnosis of knee osteoarthritis was made when knee pain is present, plus Osteophytes on radiographs, plus at least 1 of the following 3:; Age > 50 years; Morning stiffness < 30 minutes; Crepitus on active motion.
Exclusion: Patients with any previous knee surgeries or lower limb fractures; Patients who had undergone arthroscopy or treatment with intra-articular hyaluronic acid during the previous 6 months ; Use of NSAIDs one week before the screening visit ; Habitual use of psychotropic or narcotic analgesics for ≥1 week within 8 weeks prior to screening ; Chronic inflammatory diseases such as rheumatoid arthritis; Orthopedic diseases, or congenital musculoskeletal deformities, or neurological disorders that may affect or interfere with the therapeutic effect; Signs of moderately significant knee synovitis include a warm and swollen (red) knee; History and/or physical examination findings compatible with knee internal derangement (e.g, positive Thessaly test); Pregnancy; Participated in other intervention studies (strength training program or physiotherapy treatment for knee osteoarthritis) in the current period and the past 6 months .